Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:

NCT ID: NCT05966064 Recruiting - Fibrous Dysplasia Clinical Trials

DEnosumab for the Treatment of FIbrous Dysplasia/McCune-Albright Syndrome in Adults (DeFiD)

DeFiD
Start date: June 13, 2023
Phase: Phase 4
Study type: Interventional

Fibrous Dysplasia/McCune-Albright syndrome (FD/MAS) is a rare disease, consisting of the replacement of normal bone tissue with fibrous tissue. FD lesions may be isolated in one or more bones or may be associated with endocrinopathies in McCune-Albright syndrome. Bone lesions constitute of weak bone tissue, leading to higher risk of fractures, pain and decreased quality of life. There is no cure for FD lesions and current therapies failed to soothe patients' complaints or to display any effect on progression of the lesions on imaging. However, the RANKL-inhibitor Denosumab demonstrated encouraging results in mouse models and in off-label clinical use, leading to clinical, biochemical and radiographical improvements. Study's aim is to investigate whether 3-monthly Denosumab will improve the clinical, radiological and biochemical manifestations of FD bone lesions.

NCT ID: NCT05965791 Recruiting - Clinical trials for Carpal Tunnel Syndrome

Median Nerve Function During Phalen's Test

Start date: July 25, 2023
Phase:
Study type: Observational

This study will use electromyography and nerve conduction studies to evaluate median nerve function during the Phalen's wrist flexion test in different wrist positions.

NCT ID: NCT05965453 Recruiting - Clinical trials for Acute Aortic Syndrome

Evaluation of the Castor Single Branch Stent Graft in Treatment of Acute Aortic Syndrome

ECAAS
Start date: June 1, 2018
Phase:
Study type: Observational

The objective of this study to evaluate the safety and effectiveness of the Castor single branch stent graft for endovascular repair of acute aortic syndrome patients without an inadequate proximal landing zone (<15mm)

NCT ID: NCT05961995 Recruiting - Clinical trials for Cyclic Vomiting Syndrome

Heartfulness Meditation Cyclic Vomiting Syndrome

HFN in CVS
Start date: June 6, 2022
Phase: N/A
Study type: Interventional

Cyclic vomiting syndrome (CVS) is a chronic disorder of gut-brain interaction (DGBI) characterized by episodes of vomiting often triggered by stress. CVS affects 2% of the population and has a disproportionate negative impact on patients and the healthcare system. Although gastrointestinal symptoms are prominent, most patients have comorbid anxiety, depression, high degrees of psychological distress, and other negative cognitive traits that adversely affect health-related quality of life (HRQoL). This is independent of typical measures of severity of CVS and warrants treatment. Recent guidelines recommend a biopsychosocial model of care incorporating techniques like meditation to mitigate stress and improve psychological outcomes in CVS. One potential approach to improve these outcomes is the use of heartfulness (HFN) meditation. Heartfulness meditation is a secular, specific, guided meditation technique that includes progressive relaxation with a concentrated focus on the heart. It is offered virtually and is free-of charge ensuring no barriers to broad application in clinical practice. A pilot study incorporating HFN meditation in CVS significantly reduced psychological distress, perceived stress, and improved coping strategies, sleep quality, and HRQoL. Other data also show that HFN meditation improves overall well-being and reduces perceived stress. However, there are significant gaps in our understanding of the mechanism underlying HFN meditation and its effects on patient outcomes.

NCT ID: NCT05961839 Recruiting - Clinical trials for Acute Myeloid Leukemia

Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Start date: September 27, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-2921.

NCT ID: NCT05959954 Recruiting - Clinical trials for Carpal Tunnel Syndrome

Predicting Nociplastic Pain in Carpal Tunnel Syndrome Through Quantitative Sensory Testing

Start date: July 21, 2023
Phase:
Study type: Observational

This study aims to investigate the predictive value of quantitative sensory testing (QST) in identifying patients with carpal tunnel syndrome (CTS) who are at risk of developing nociplastic pain.

NCT ID: NCT05956106 Recruiting - Metabolic Syndrome Clinical Trials

Effect of Mulberry Fruit Powder in Metabolic Syndrome

Start date: August 1, 2023
Phase: N/A
Study type: Interventional

Metabolic syndrome is a raising concern globally, especially in developing countries such as Pakistan. To prevent its risk factors diet and lifestyle modification is major solution. Functional foods have additional benefits of treating disease while providing basic nutrients. Mulberry is a native fruit with the properties of functional food, it is rich in anthocyanin and different anti-obesity,anti-diabetic, and anti-hyperlipidemic treating potential antioxidants. Mulberry will prove its therapeutic potential against the risk factors of metabolic syndrome.

NCT ID: NCT05954325 Recruiting - Fatigue Clinical Trials

Immunoadsorption vs. Sham Treatment in Post COVID-19 Patients With Chronic Fatigue Syndrome

Start date: August 15, 2023
Phase: N/A
Study type: Interventional

The complex clinical symptoms of post COVID syndrome, especially chronic fatigue, pose a major challenge to patients and to the health care system and are frequently refractory to therapeutic intervention. There is increasing evidence that a dysregulated post-viral immune response may be involved in the pathogenesis of post COVID syndrome. In uncontrolled case studies, an improvement of fatigue symptoms after removing autoantibodies has been reported in post COVID patients. However, there is a lack of prospective, sham controlled studies. We initiate an interventional, randomised, sham treatment-controlled prospective study, the EXTINCT post COVID study, which aims to scientifically test the therapeutic efficacy of an extracorporeal apheresis procedure (immunoadsorption) for the treatment of a well characterized cohort of patients with post COVID syndrome, while at the same time providing basic research evidence for an understanding of the pathogenesis of post COVID syndrome. Thereby, we expect to obtain important insights into the diagnosis, treatment and pathophysiology of post-COVID syndrome.

NCT ID: NCT05953311 Recruiting - Clinical trials for Intensive Care Unit Syndrome

Neurological Blood-based Biomarkers and Cognitive Disorders in Critically Ill Survivors.

COGNISI
Start date: June 23, 2023
Phase:
Study type: Observational

Cognitive disorders are common after intensive care. Currently, their diagnosis is based on clinical tests. The investigators plan to study the relationship between different neurological blood biomarkers (cytokines, S100β protein, neuron specific enolase, total Tau protein and neurofilament light chain) and the occurrence of cognitive disorders during the three months following intensive care discharge.

NCT ID: NCT05951933 Recruiting - Clinical trials for Subacromial Pain Syndrome

Transcranial Electrical Stimulation in Subacromial Pain Syndrome

Start date: November 23, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to analyze whether a physiotherapy protocol based on strengthening exercises to the shoulder girdle muscles carried on during anodal transcranial electrical stimulation (a-TES) is more effective on the symptoms and functionality of subjects with subacromial pain syndrome than an isolated strengthening program. The main questions it aims to answer are: - Is the strengthening + a-TES protocol effective on functionality? - Is the strengthening + a-TES protocol effective on quality of life? - Is the strengthening + a-TES protocol effective on pain? - Is the strengthening + a-TES protocol effective on muscle strength? - Is the strengthening + a-TES protocol effective on active range of movement? - Is the strengthening + a-TES protocol effective on proprioception? - Is the strengthening + a-TES protocol effective on posture? - Is the strengthening + a-TES protocol effective on glenohumeral and scapulothoracic kinematics? Participants will perform an 8 weeks-3 days/week shoulder strengthening protocol for the rotator cuff and scapulothoracic muscles using elastic bands and dumbbells. The rotator cuff exercises will be performed while they receive a-TES using a neoprene helmet with the electrodes placed in the opposite hemisphere to the affected side. The scapulothoracic exercises will be performed without the transcranial stimulation. The experimental group will receive real a-TES, and will be compared with a control group that will perform the same therapeutic exercises but with placebo a-TES to see the effectiveness of the a-TES on the outcomes cited above.